Category: Parkinson's Disease: Cognitive functions
Objective: To summarize the effect of subthalamic nucleus (STN) or globus pallidus internus (GPi) DBS on cognition, quality of life, and non-motor symptoms in patients with Parkinson’s Disease (PD).
Background: DBS improves motor outcomes and quality of life in patients with PD. The ADROIT NAPA sub-study will evaluate non-motor and cognitive changes after DBS.
Method: ADROIT is a large, international, prospective, post-market, observational study at up to 50 centers worldwide that collects long-term safety and effectiveness data on Abbott DBS systems in the real-world setting. Cognitive assessment with MoCA, non-motor evaluations with MDS-UPDRS I, and quality of life with PDQ-39 were summarized for PD patients after receiving STN or GPi DBS.
Results: As of October 2023, there have been 340 PD patients enrolled in the study with 313 STN and 27 GPi newly implanted DBS systems at 38 sites in the US, Europe, and Asia-Pacific. On average at 1 year, DBS improved MDS-UPDRS III motor scores by 54% after STN DBS and 50% after GPi DBS. Average MoCA scores were 25.5 ± 3.6 at baseline (n=238) and 24.9 ± 4.4 at 1 year (n=121) in the STN group. Corresponding scores for the GPi group were 24.3 ± 3.7 (n=12) and 25.9 ± 2.4 (n=8). Average MDS-UPDRS I score was 11.1 ± 5.9 at baseline (n=270) and 10.8 ± 6.7 at 1 year (n=144) in the STN group. Corresponding scores for the GPi group were 10.1 ± 4.5 (n=17) and 12.7 ± 6.5 (n=6).
Conclusion: The ADROIT global observational study can provide large scale results on cognitive state, quality of life, and non-motor evaluations in PD patients treated with DBS. This interim report will summarize available 1-year paired data for non-motor assessments including MoCA, MDS-UPDRS I, and PDQ-39 and address clinical dynamics for distinct patient groups with STN and GPi implantations.
To cite this abstract in AMA style:
M. Potter-Nerger, A. Gharabaghi, C. Torres Diaz, A. Schnitzler, S. Chen, L. Himes, M. Frassica, D. Nanduri, S. Groppa. Cognitive, Non-Motor, and Quality of Life Outcomes After STN or GPi DBS for Parkinson’s Disease: An Interim Report from the ADROIT NAPA Sub-Study [abstract]. Mov Disord. 2024; 39 (suppl 1). https://www.mdsabstracts.org/abstract/cognitive-non-motor-and-quality-of-life-outcomes-after-stn-or-gpi-dbs-for-parkinsons-disease-an-interim-report-from-the-adroit-napa-sub-study/. Accessed October 1, 2026.« Back to 2024 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/cognitive-non-motor-and-quality-of-life-outcomes-after-stn-or-gpi-dbs-for-parkinsons-disease-an-interim-report-from-the-adroit-napa-sub-study/